ImmunityBio, Inc. (IBRX) Stock: Price, Forecast & Analyst Target
ImmunityBio, Inc. (IBRX) — MoonshotScore 13/100 (Weak band), calculated Oct 5, 2026. Price $10.28 (-0.10%), as of the Oct 5, 2026 trading session; market cap $10.8B. Expected results Nov 3, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 30.22× (market value Oct 5, 2026; cash Jun 30, 2026) · expected results Nov 3, 2026
ImmunityBio, Inc. · IBRX · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Nasdaq-listed ImmunityBio develops immunotherapies and cell therapies for cancers and infectious diseases, while reported revenue now comes overwhelmingly from product sales. That makes it more than a pipeline biotechnology story, but not yet a self-funding commercial company. The case depends on whether rising product revenue can overtake research, selling, and financing demands before cash consumption forces further balance-sheet action.
Price as of Oct 5, 2026
Key Statistics
MoonshotScore v2 · ImmunityBio (IBRX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, but weak quality; the market is already moving on it. Business Quality: Thin; Financial Safety: Okay; Valuation: Full; Growth Durability: Growing; Momentum: Surging.
- quarterly revenue $51M (Q2 FY2026, quarter ended Jun 2026)
- EPS beat 4 of 8
- Altman Z -10.18 · Piotroski F 3
Holding back: weak fundamentals
Helping: durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 13 | Weak | |
| 12 | Weak | |
| 12 | Weak | |
| 13 | Weak | |
| 13 | Weak | |
| 13 | Weak |
The score was 13 in the stored Oct 4, 2026 snapshot and remains 13 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Business Quality -1 and Growth Durability -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $10.28 | |
| Change on the day | -0.10% | |
| 52-week range | $1.95–$12.43 | |
| Market capitalisation | $10.8B | |
| Shares traded on the day | 5.8M | |
| Beta (volatility vs the S&P 500) | 0.14 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for ImmunityBio (IBRX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 6, 2026, except a card that shows its own read date.
Watch the IBRX film — every key number, told as a short cinematic story
~2 min · open the film
What is ImmunityBio (IBRX), and what does it report?
Short answer · as of
ImmunityBio combines antibody-cytokine fusion proteins, immune-modulating agents, vaccines, natural killer cell therapies, and adaptive T-cell approaches across cancer and infectious-disease programs.
Research dated 2026-09-13.
ImmunityBio combines antibody-cytokine fusion proteins, immune-modulating agents, vaccines, natural killer cell therapies, and adaptive T-cell approaches across cancer and infectious-disease programs. Its economics therefore span commercial product sales and the continuing cost of advancing a broad therapeutic platform.
Reported revenue is almost entirely product revenue, with other product-and-service activity contributing little. The income statement is measuring an emerging commercial business inside a research-heavy biotechnology company, not merely collaboration payments from an otherwise pre-revenue pipeline.
What do the latest results show for ImmunityBio (IBRX)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $51M.
Research dated 2026-09-13.
Revenue has increased throughout the reported quarterly series, and gross profit has remained close to revenue as sales scaled. In the latest period, revenue exceeded the prevailing estimate and the operating loss narrowed, even though research and selling costs together remained well above gross profit.
The commercial progress did not translate into proportionate bottom-line improvement. Net loss and per-share loss were far worse than expected, while operating cash use accelerated sharply; the large separation between operating loss and net loss shows that the headline result was not driven by the core operating deficit alone.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $51.24M Jun 30, 2026
- Latest quarter · R&D
- $57.69M Jun 30, 2026
- Latest quarter · SG&A
- $50.63M Jun 30, 2026
- Latest quarter · FMP standardized operating result
- −$61.70M Jun 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | $51.24M | $57.69M | $50.63M | −$61.70M |
| Mar 31, 2026 | $44.21M | $64.77M | $44.46M | −$69.79M |
| Dec 31, 2025 | $38.28M | $60.81M | $37.83M | −$64.68M |
| Sep 30, 2025 | $32.06M | $50.73M | $32.83M | −$55.63M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $51.24M Aug 4, 2026
- Latest report · revenue estimate
- $49.70M Aug 4, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 4, 2026
- Latest report · EPS vs estimate
- Below estimate Aug 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 4, 2026 | $51.24M | $49.70M | −$0.2200 | −$0.0800 |
| May 7, 2026 | $44.21M | $43.07M | −$0.6200 | −$0.0800 |
| Feb 23, 2026 | $38.28M | $38.36M | −$0.0600 | −$0.0800 |
| Nov 4, 2025 | $32.06M | $37.78M | −$0.0700 | −$0.1000 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $51M | -$230M | -$0.22 (diluted) |
| Q1 FY2026 | $44M | -$633M | -$0.62 (diluted) |
| Q4 FY2025 | $38M | -$62M | -$0.06 (diluted) |
| Q3 FY2025 | $32M | -$67M | -$0.07 (diluted) |
What are the financial strengths and risks for ImmunityBio (IBRX)?
Short answer
Cash and short-term investments were $357.37M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$66.49M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
High gross margins and rising product sales are the clearest financial strengths. Cash and short-term investments also support strong near-term liquidity ratios, and the cash balance has improved substantially from its earlier low.
Those strengths sit against debt that materially exceeds cash, persistent operating losses, and a recent acceleration in cash consumption. The estimated runway is limited at the current spending rate, while distress and quality screens remain weak; a stalled product ramp combined with continued research spending would bring financing pressure forward.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -10.18 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$66.49M Jun 30, 2026
- Previous quarter · operating cash flow
- −$75.36M Mar 31, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Jun 30, 2026 | −$66.49M | −$3.54M |
| Mar 31, 2026 | −$75.36M | −$1.79M |
| Dec 31, 2025 | −$70.38M | −$1.27M |
| Sep 30, 2025 | −$68.91M | −$770,000 |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at ImmunityBio (IBRX)?
Short answer · as of
The next earnings report is expected on Nov 3, 2026.
Research dated 2026-09-13.
Product revenue, operating loss, and operating cash use belong on the same scorecard at the scheduled earnings update. A stronger commercial transition would pair continued sales growth with a narrowing operating deficit and slower cash depletion; another wide gap between operating and net loss would keep attention on financial burdens outside core operations.
Liquidity should be tracked against debt and the current burn rate, not viewed in isolation. Longer-range analyst estimates assume a steep revenue expansion, yet their range is broad and the contributing analyst base thins materially, making actual product-sales progression more informative than the distant averages.
How does ImmunityBio compare with its peers?
Short answer
ImmunityBio's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
ImmunityBio differs from pre-revenue biotechnology peers because product sales are already material and carry high reported gross margins. It also differs from mature specialty pharmaceutical businesses because research spending, operating losses, cash burn, and leverage still dominate the financial profile.
That hybrid structure makes commercial execution unusually important: product adoption must fund a platform spanning natural killer cells, adaptive T cells, vaccines, and engineered immune therapies. Pipeline breadth may create additional opportunities, but it also sustains costs while the marketed-product base is still developing.
| Company | Price | Market value | Score |
|---|---|---|---|
| $335.90 Oct 5, 2026 | $9.50B | 98 5-pillar Oct 5, 2026 | |
| $59.36 Oct 5, 2026 | $14.8B | 98 5-pillar Oct 5, 2026 | |
| $108.89 Oct 5, 2026 | $12.9B | 97 5-pillar Oct 5, 2026 | |
| $72.56 Oct 5, 2026 | $11.3B | 93 5-pillar Oct 5, 2026 | |
| $146.48 Oct 5, 2026 | $14.4B | 92 5-pillar Oct 5, 2026 | |
| $120.80 Oct 5, 2026 | $12.6B | 91 5-pillar Oct 5, 2026 | |
| $30.20 Oct 5, 2026 | $8.54B | 89 5-pillar Oct 5, 2026 | |
| $228.32 Oct 5, 2026 | $14.2B | 88 5-pillar Oct 5, 2026 | |
| $141.61 Oct 5, 2026 | $9.01B | 75 5-pillar Oct 5, 2026 | |
| $159.50 Oct 5, 2026 | $6.40B | 69 5-pillar Oct 5, 2026 | |
| $57.60 Oct 5, 2026 | $11.1B | 65 5-pillar Oct 5, 2026 | |
| $53.60 Oct 5, 2026 | $8.31B | 65 5-pillar Oct 5, 2026 | |
| ImmunityBio (IBRX) — this page | $10.28 | $10.8B | 13 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $12.00 – $12.00
- Consensus target
- $12.00
- Median target
- $12.00
Consensus record · Captured .
Measured against a quoted price of $10.28 (as of Oct 5, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 2, 2026
- Transactions
- 28
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 6
- Other transactions
- 22
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 19.5% Period end Jun 30, 2026
- Previous quarter · ownership
- 17.4% Prior to period end Jun 30, 2026
- Reporting holders
- 438 Period end Jun 30, 2026
- Previous quarter · holders
- 418 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 34,083,262 |
| State Street Corp | 21,398,438 |
| Vanguard Portfolio Management LLC | 17,863,911 |
| Vanguard Capital Management LLC | 15,691,579 |
| D. E. Shaw & Co., INC. | 11,551,019 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about ImmunityBio (IBRX)?
- Biotech Lagged The Broader Market In September — Did Retail Favorites SLS, IBRX, VNDA And IOVA Dodge XBI’s Slump?
- SLS, IBRX, IOVA In Focus Amid Big Pharma’s Early Cancer-Asset Hunt: J&J Flags M&A ‘Sweet Spot,’ Pfizer Eyes Phase 1-2 Deals
- SLS, IBRX Stocks Draw Investor Attention With Major Cancer Conferences And New Drug Data On Deck
- SLS, IBRX In Focus: Canadian Insurance Giant Manulife’s Unit Raises Stakes Ahead Of Key Cancer Catalysts
ImmunityBio Healthcare Stock: Key Questions Answered
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
How do ImmunityBio’s natural killer cell and adaptive T-cell platforms fit its business?
They form part of a wider immunotherapy suite that also includes antibody-cytokine fusion proteins, immune-modulating agents, and vaccine technologies. The platform targets cancers and infectious diseases, so commercial product sales coexist with substantial continuing research activity.
Why does rising product revenue not yet make ImmunityBio self-funding?
Gross profit has grown with product sales, but research and selling costs remain larger than gross profit and operations continue to consume cash. Commercial growth therefore has not yet absorbed the cost of the wider platform.
What makes ImmunityBio’s latest net loss different from its operating loss?
The operating deficit narrowed while the net loss remained far larger, creating an unusually wide separation between core operating performance and the bottom line. The per-share result also missed expectations despite revenue exceeding the estimate.
Can ImmunityBio fund its immunotherapy rollout from current cash?
Current cash and short-term investments support near-term liquidity, but they remain below total debt and imply limited runway at the prevailing burn rate. Continued product growth, slower cash use, or additional financing would be needed to extend that position.
What is the IBRX stock price today?
The last price recorded on this page for ImmunityBio, Inc. (IBRX) is $10.28, as of the Oct 5, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the IBRX price target?
The analyst consensus price target for ImmunityBio, Inc. (IBRX) is $12.00 (range $12.00 to $12.00, median $12.00), per FMP data captured Oct 5, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (81 figures)
The 81 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 1 fact from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
id.hq | SEC filing business address | SAN Diego, CA | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "3530 John Hopkins Court, San Diego, CA, 92121, US". |
FMP — 73 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Nov 3, 2026 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $10.28 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T14:19:33.000Z. | |
px.change | Change on the day | -0.10% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $10.8B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-05. FMP quote timestamp: 2026-10-05T14:19:33.000Z. Captured from FMP at 2026-10-05T14:19:37.691Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.01 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q2 FY2026 | $51M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $1.95–$12.43 | FMP | Financial Modeling Prep (FMP) quote | |
px.volume | Shares traded on the day | 5.8M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.14 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Richard Gerald Adcock | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.founder | Founder named in the filing | Patrick Soon-Shiong FRCS — Founder, Executive Chairman and Global Chief Scientific & Medical Officer | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 688 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $930,000, net result −$346.79M; FY2022 revenue $240,000, net result −$416.57M; FY2023 revenue $620,000, net result −$583.20M; FY2024 revenue $14.75M, net result −$413.56M; FY2025 revenue $113.29M, net result −$351.40M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Product $112.98M · Product and Service, Other $306,000 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 94.6% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $51.24M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.rd_k | R&D — period end 2026-06-30 | $57.69M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $50.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | −$61.70M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $44.21M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.rd_k | R&D — period end 2026-03-31 | $64.77M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $44.46M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | −$69.79M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $38.28M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.rd_k | R&D — period end 2025-12-31 | $60.81M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $37.83M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$64.68M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.revenue_k | Revenue — period end 2025-09-30 | $32.06M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.rd_k | R&D — period end 2025-09-30 | $50.73M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.sga_k | SG&A — period end 2025-09-30 | $32.83M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-09-30.operating_result_k | FMP standardized operating result — period end 2025-09-30 | −$55.63M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-08-04.revenue_actual | Revenue · reported — report date 2026-08-04 | $51.24M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.revenue_estimated | Revenue · estimate — report date 2026-08-04 | $49.70M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_actual | EPS · reported — report date 2026-08-04 | −$0.2200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-04.eps_estimated | EPS · estimate — report date 2026-08-04 | −$0.0800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_actual | Revenue · reported — report date 2026-05-07 | $44.21M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.revenue_estimated | Revenue · estimate — report date 2026-05-07 | $43.07M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_actual | EPS · reported — report date 2026-05-07 | −$0.6200 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-05-07.eps_estimated | EPS · estimate — report date 2026-05-07 | −$0.0800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.revenue_actual | Revenue · reported — report date 2026-02-23 | $38.28M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.revenue_estimated | Revenue · estimate — report date 2026-02-23 | $38.36M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.eps_actual | EPS · reported — report date 2026-02-23 | −$0.0600 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-23.eps_estimated | EPS · estimate — report date 2026-02-23 | −$0.0800 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_actual | Revenue · reported — report date 2025-11-04 | $32.06M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.revenue_estimated | Revenue · estimate — report date 2025-11-04 | $37.78M | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_actual | EPS · reported — report date 2025-11-04 | −$0.0700 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-11-04.eps_estimated | EPS · estimate — report date 2025-11-04 | −$0.1000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $357.37M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$66.49M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-06-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $0.00 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $813.06M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$66.49M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | −$75.36M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$3.54M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$1.79M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$70.38M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | −$1.27M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.operating_cash_flow_m | Operating cash flow — period end 2025-09-30 | −$68.91M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-09-30.capex_m | Capital expenditure (reported) — period end 2025-09-30 | −$770,000 | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $12.00 – $12.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $12.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $12.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 5, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 28 transactions · 0 purchases, 6 sales, 22 other transactions · 7 identified insiders · of the newest 100 records, those within the last 180 days, newest dated Jul 2, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.ownership_pct | Institutional ownership | 19.5% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.ownership_pct_previous_quarter | Previous quarter · ownership | 17.4% | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.institutions.depth.holders | Reporting holders | 438 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 418 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 34,083,262 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | State Street Corp — shares in provider snapshot | 21,398,438 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 17,863,911 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Vanguard Capital Management LLC — shares in provider snapshot | 15,691,579 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | D. E. Shaw & Co., INC. — shares in provider snapshot | 11,551,019 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 2 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-15 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z -10.18 · Piotroski F 3 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 30.22× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $357.37M at Jun 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-05. Balance-sheet reference date: 2026-06-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-08-04.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($51.24M) with the recorded estimate ($49.70M) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-04.eps_actual.comparison | Latest report · EPS vs estimate | Below estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS (−$0.2200) with the recorded estimate (−$0.0800) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 13 of 100 · Weak · pillars 33 / 48 / 49 / 72 / 94 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 13 (stored snapshot Oct 4, 2026) → 13 (current publication computed Oct 5, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-06-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.rd_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.rd_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.rd_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k,fin.q_table.depth.2025-09-30.revenue_k,fin.q_table.depth.2025-09-30.rd_k,fin.q_table.depth.2025-09-30.sga_k,fin.q_table.depth.2025-09-30.operating_result_k. - Earnings-history note. Source series as of 2026-08-04. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-04.revenue_actual,earn.history.depth.2026-08-04.revenue_estimated,earn.history.depth.2026-08-04.revenue_actual.comparison,earn.history.depth.2026-08-04.eps_actual.comparison,earn.history.depth.2026-08-04.eps_actual,earn.history.depth.2026-08-04.eps_estimated,earn.history.depth.2026-05-07.revenue_actual,earn.history.depth.2026-05-07.revenue_estimated,earn.history.depth.2026-05-07.eps_actual,earn.history.depth.2026-05-07.eps_estimated,earn.history.depth.2026-02-23.revenue_actual,earn.history.depth.2026-02-23.revenue_estimated,earn.history.depth.2026-02-23.eps_actual,earn.history.depth.2026-02-23.eps_estimated,earn.history.depth.2025-11-04.revenue_actual,earn.history.depth.2025-11-04.revenue_estimated,earn.history.depth.2025-11-04.eps_actual,earn.history.depth.2025-11-04.eps_estimated. - Cash-flow note. Source series as of 2026-06-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m,fin.opcf.depth.2025-09-30.operating_cash_flow_m,fin.opcf.depth.2025-09-30.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | ImmunityBio, Inc. | 2026-02-23 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-23 |
| Ticker / exchange | IBRX on Nasdaq | 2026-09-13 | OFFICIAL | SEC EDGAR filer record |
| Business description | ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Product: $112.98M; Product and Service, Other: $306,000 | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Cash, investments and debt | Total debt: $813.06M; Liquidity basis: cash and short-term investments; Total liabilities: $1.67B; Cash and short-term investments: $357.37M; Cash and investments: $357.40M; Long-term investments: $0; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology The company's SEC filings classify it under SIC 2836 — Biological Products, (No Diagnostic Substances). | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Trailing twelve-month ratio set | Quick ratio: 5.7; Current ratio: 5.72; Debt to equity: -0.78; Net margin: -598.6%; Gross margin: 94.6%; Operating margin: -151.9%; Return on assets: -157.9%; Return on equity: 135% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-08-04 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-08-04 | OFFICIAL | SEC EDGAR filer submissions | |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $357.40M; Cash and short-term investments: $357.40M; Long-term investments: $0; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash runway cross-check (ours) | Years: 1; Method: cash and short-term investments of $357.4M at 2026-06-30 divided by the annualized rate at which operations and capital spending used cash ($361.1M per year); Reaches: 2027-06; Cash basis: cash and short-term investments; Cash: $357.40M; Annualized cash use: $361.10M Rate taken from operating cash flow less capital expenditure over the 8 most recent reported quarters, annualized.; Measured from operations, not from the change in the cash balance — a company that raised money during the window would otherwise appear to be burning less than it is.; Assumes that rate continues unchanged: it ignores announced cost reductions, financing already arranged and any change in spending.; Assumes the reported cash and short-term investments are realizable for funding operations; restrictions and timing of access are not established by these provider fields. Long-term investments are excluded.; It is a cross-check, not a forecast, and the company's own statement about its runway outranks it. | 2026-06-30 | COMPUTED | Computed from reported cash flow; assumptions stated |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: -$455.70M; Total debt: $813.10M; Cash and investments: $357.40M Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Distress and quality screens | Altman Z-score: -11.07; Piotroski F-score: 3 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2026-11-03; EPS estimate: -$0.08 per share; Revenue estimate: $59.23M The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
At most 3 analysts contributed — treat this as thin coverage, not a consensus. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Recent SEC filings |
| 2026-08-04 | OFFICIAL | SEC EDGAR filer submissions |
Data provided for informational purposes only.